Dexcom announced the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with diabetes will ...
NEW YORK - November 18, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in DexCom, Inc. (NASDAQ: DXCM) of a class action securities lawsuit.
The average one-year price target for DexCom (NasdaqGS:DXCM) has been revised to $88.30 / share. This is a decrease of 13.54% ...
Zacks Investment Research on MSN
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal
DexCom DXCM recently announced that it has received FDA clearance for its CGM-integrated basal insulin dosing optimizer, ...
Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...
Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback